<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/214276-novel-compounds-for-the-management-of-aging-related-and-diabetic-vascular-complications-process-for-their-preparation-and-composition-comprising-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:56:33 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 214276:NOVEL COMPOUNDS FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND COMPOSITION COMPRISING THEM.</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL COMPOUNDS FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND COMPOSITION COMPRISING THEM.</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>TITLE: NOVEL COMPOUNDS FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND COMPOSITION COMPRISING THEM. The invention disclose novel compounds of the pyridinium series useful for the managment of diabetes and aging-related vascular complilcations, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disprders and discoloration of teeth by breakeing performed AGE. The invention also discloses, method for preparation of the novel compounds of the series and pharmaceutical composition having one or more compounds as defined above as active ingredients.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FIELD OF THE INVENTION<br>
The present invention relates to a new class of compounds of pyridinium<br>
series and to their use in treatment of diabetes and related illnesses. More<br>
particularly the invention relates to compounds of this series, methods for their<br>
preparation, pharmaceutical composition containing these compounds and their<br>
use in the treatment of complications of diabetes mellitus. The compounds of this<br>
series exhibit AGE breaking activity, which is essential for the treatment of<br>
diabetic and aging-related complications including kidney disease, nerve damage,<br>
atherosclerosis, retinopathy and dennatological conditions. The invention also<br>
extends to the method of reversing the discoloration of teeth resulting from<br>
nonenzymatic browning in the oral cavity which comprises administration of an<br>
amount effective to reverse pre-formed advanced glycosylation crosslinks.<br>
BACKGROUND OF THE INVENTION<br>
Maillard in 1912 found that reducing sugars, such as glucose and ribose<br>
react with proteins to form brown pigments. Further studies have shown that this<br>
is an irreversible non-enzymatic reaction, which occurs in several natural systems<br>
including stored foodstuff. Maillard reaction occurs in two stages, early and<br>
advanced. Initially, proteins react with glucose to form stable Amadori products,<br>
which subsequently cross-links to form advanced glycation end products (AGE).<br>
In most cases, the formation of AGE also accompanies browning of the proteins<br>
and increase in the fluorescence.<br>
In diabetes, where blood glucose level is significantly higher than normal,<br>
the reaction of glucose with several proteins such as haemoglobin, lens crystallin<br>
and collagen, gives rise to the formation of AGE, which in turn, is responsible for<br>
the complications associated with diabetes, such as nephropathy,<br>
microangiopathy, endothelial dysfunction and other organ dysfunctions. In<br>
addition, the activity of several growth factors, such as basic fibroblast growth<br>
factor, is also impaired. AGE products, unlike normal proteins in tissue, have a<br>
slower rate of turnover and replenishment. It has been reported that AGE<br>
products may in fact elicit a complex immunological reaction involving RAGE<br>
(Receptor for Advanced Glycation End Products) receptors and activation of<br>
several incompletely defined immunological processes. It has been documented<br>
that diabetes with evidence of microangiopathy and macroangiopathy also show<br>
evidence of oxidative stress, the mechanism of which has not been elucidated.<br>
In vitro AGE formation can be studied in the laboratory by incubating<br>
reducing sugars, such as ribose or glucose with bovine serum albumin. AGE<br>
formation can be detected by increase in the fluorescence or increased cross<br>
reactivity with anti-AGE antibodies. The increase in fluorescence seems to<br>
precede formation of AGE specific antigenic epitopes. This increase in<br>
fluorescence is used to monitor the increased AGE formation in vitro (Brownlee<br>
M et al, Science 1986; 232:1629-1632). In addition to the increase in the<br>
fluorescence, one of the most important features of in vitro AGE formation is the<br>
formation of antigenic epitopes that are specific to AGE and not to the native<br>
proteins. Therefore, it is possible to raise antibodies against advanced glycation<br>
end products of one protein and use them to detect AGE formation in other<br>
proteins. This has served as an important analytical tool in AGE research.<br>
Due to the clinical significance of AGE formation, many approaches are<br>
being used to diagnose, prevent, or revert AGE formation in the body. The<br>
formation of AGE could be inhibited by reacting with an early glycosylation<br>
product that results from the original reaction between the target protein and<br>
glucose. The inhibition was believed to take place as the reaction between the<br>
inhibitor and the early glycosylation product appeared to interrupt the subsequent<br>
reaction of the glycosylated protein with additional protein material to form the<br>
cross linked late stage product. Compounds like aminoguanidine act to inhibit<br>
AGE formation by such mechanism.<br>
The formation of AGE on long-lived proteins is also associated with cross-<br>
linking of these proteins. The AGE derived protein cross-links have been shown<br>
to be cleaved by compounds like N- phenacyl thiazolium bromide (PTB), which<br>
reacts with and cleaves covalent, AGE derived protein cross links (Vasan et al.<br>
Nature 1996; 382: 275-278 ; US 5,853,703, Date of Patent : Dec. 29, 1998). The<br>
mechanism of reducing the AGE content in tissues is expected to take place<br>
relatively rapidly, in contrast to aminoguanidine, which acts slowly by its very<br>
nature of mechanism of action. This current specification is related to compounds<br>
of pyridinium class, which break pre-formed AGE, like PTB, and in some cases<br>
even more effectively by than PTB.<br>
SUMMARY OF THE INVENTION<br>
The main objective of the present invention is to provide a new class of<br>
compounds of the pyridinium series which are useful for the management of<br>
diabetes and aging related vascular complications and particularly in the treatment<br>
of complications of diabetes mellitus and other aging related conditions including<br>
kidney disease, nerve damage, atherosclerosis, retinopathy and dermatological<br>
conditions. The invention also extends the method to reverse the discoloration of<br>
teeth resulting from nonenzymatic browning in the oral cavity which comprises<br>
administration of an amount effective to reverse the pre-formed advanced<br>
glycosylation crosslinks, etc.<br>
Another object of the present invention is to provide compounds of the<br>
pyridinium series, which exhibit AGE breaking activities.<br>
Yet another object of the present invention is to provide a method of<br>
preparation of compounds of the pyridinium series which exhibit AGE breaking<br>
activities.<br>
Still another object of the invention is to provide pharmaceutical<br>
compositions with a new class of compounds of the pyridinium series according<br>
to the invention and their pharmaceutically acceptable salts in combination with<br>
suitable carriers, solvents, excepients, diluents and other media normally<br>
employed in preparing such compositions.<br>
Still another object of the invention is to provide a method of treatment of a<br>
diabetic patient by administration of the compounds of the invention, either singly<br>
or in combination with drugs for anti-diabetic therapy, or pharmaceutically<br>
acceptable salts thereof in required dosage in admixture with pharmaceutically<br>
acceptable diluent, solvent, excepients, carriers or other media as may be<br>
appropriate for the purpose.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
The present invention provides for a new class of AGE breakers, of general<br>
formula I, <br>
wherein<br>
R1 is -R4-R5 or -N(R7) N (R7) R9;<br>
R4 is selected from the group -N(R7)R6O, -N(R7)R6N(R7)-, OR6O, -OR6N(R7)-,<br>
where Re is alkyl;<br>
R5 is selected from the group alkyl, aryl, including heteroaryl, -COR7, SO2R7,<br><br>
where R7 is selected from the group H, alkyl or aryl, including heteroaryl;<br>
R2 is selected from the group F, Cl, Br, I, OR7, NO2, alkyl, aryl including<br>
heteroaryl, formyl, acyl, C(O)NR7R10, C(O)OR7, NR7R10, N=C(R7)(R10), SR7,<br>
SO2NH2, SO2 alkyl and SO2aryl,<br>
and m is 0, 1 or 2<br>
R3 is selected from the group R7, OR7, N(R7) (R10), N=C(R7) (Rio), N(R7) N(R7)<br>
(R10), N(R7) N=C(R7) (R,o) and CH(R7)C(O)R8<br>
where Rs is selected from the group R7, OR7 and NR7R10;<br>
R9 is selected from the group consisting of hydrogen, alkyl, aryl, including<br>
heteroaryl, C(O)R10, -SO2R10, -C(S)NHR10, -C(NH) NH (R10), -C(O) NHR10,<br>
Rio is selected for the group H, alkyl or aryl, including heteroaryl and in each<br>
case optionally different from substituent R7<br>
X is selected from group consisting of a halide ion, acetate ion, perchlorate ion,<br>
sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion,<br>
carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate<br>
ion, BF4-, PF6-, etc.<br>
with proviso that<br>
(i) when two alkyl groups are present on the same carbon or nitrogen, they are<br>
optionally linked together to form a cyclic structure and<br>
(ii) the nitrogen of heteroaryl ring of R10, when present, is optionally<br>
quaternized with compound such as X-CH2C(O)-R.3<br>
As used herein, "alkyl" refers to an optionally substituted hydrocarbon<br>
group joined by single carbon-carbon bonds and having 1 to 8 carbon atoms<br>
joined together. The alkyl hydrocarbon group may be linear, branched or cyclic,<br>
saturated or unsaturated. The substituents are selected from F, Cl, Br, I, N, S, 0<br>
and aryl. Preferably, no more than three substituents are present.<br>
As used herein "aryl" refers to an optionally substituted aromatic group<br>
with atleast one ring having a conjugated pi- electron system, containing upto two<br>
conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl<br>
and biaryl groups, all of which may be optionally substituted. The substituents are<br>
selected from F, Cl, Br, I, N, S. O and straight chain or branched C1-C6<br>
hydrocarbon.<br>
The novel compounds of the invention of general formula I having m as 0<br>
and - COR1 at position 3 are listed in Table 1A and the novel compounds of the<br>
invention of general formula I having m as 0 and - COR1 at position 4 are listed in<br>
Table 1B. The following compounds suggested are by way of example alone of<br>
the representative compounds of the general formula I as defined above and in no<br>
way restrict the invention.<br>
l-[1-(2-thien-2-yl-2-oxoethyl)-6-methyl-3-carbonylpyridinium]-2-[l-<br>
(2-Thien-2"-yl-2-oxoethyl )-3-carbonyl pyridinium ] hydrazine<br>
dichloride(compound no: 1).<br>
1 -(2-thien-2"-yl-2-oxoethyl)-3-(isopropylsulfonyl hydrazino carbonyl)<br>
pyridiniiun broraide(compound no: 2.).<br>
1-(2-(4-benzyl piperidin-1 -yl)-2-oxoethyl)-3-(methanesulfonyl<br>
hydrazino carbonyl) pyridinium chloride(compound no: 3 ).<br>
1-(2-(2-ethoxy carbonyl pyrrolidin-l-yl)-2-oxoethyl)-3-(methanesulfonyl<br>
hydrazino carbonyl) pyridinium chloride, (compound no: 40-<br>
1-(2-thien-2"-yl-2-oxoethyl)-3-(raethanesulfonyl hydrazino carbonyl )-5-<br>
bromo pyridinium bromide, (compound no: 5").<br>
1-(2-thien-2"-yl-2-oxoethyl)-3-(ethoxycarbonyl hydrazino carbonyl)<br>
pyridinium bromide, (compound no: 6 ).<br>
1-(2-(5-chlorothien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl) pyridinium bromide (compound no: 1 ).<br>
N,N"-bis[3-carbonyl-1-(2-(4-nitrothien-2-yl)-2-oxoetJiyl)pyridinium]<br>
hydrazine dichloride. (compound no: 8).<br>
1-(2-thien-2"-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)<br>
-6-methyl pyridinium bromide, (compound no: 9 ).<br>
N,N"-bis[3-carbonyl-1-(2-(5-methylthien-2-yl)-2-oxoethyl) pyridinium]<br>
hydrazine dichloride. (compound no: 10).<br>
N,N"-bis[3-carbonyl-1-(2-(2-ethoxycarbonyl pyrrolidin-l-yl)-2-<br>
oxoethyl) pyridinium] hydrazine dichloride. (compound no:n ).<br>
1-[1-(2-thien-2"-yl-2-oxoethyl)-5-aminocarbonyl-3-carbonyl<br>
pyridinium]-2-[1-(2-Thien-2"-yl-2-oxoethyl )-3-carbonyl pyridinium]<br>
hydrazine dichloride (compound no: 12).<br>
1-(2-(4-carbethoxy-thiazolidin-3-yl)-2-oxoethyl)-3-(methanesulfonyl<br>
hydrazino carbonyl) pyridinium chloride (compound no: 13 ).<br>
N,N"-bis[3-carbonyl-1-(2-(5-chlorothien-2-yl)-2-oxoethyl)pyridinium]<br>
hydrazine dichloride. (compound no: 14).<br>
1-(2-(5-methylthien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl) pyridinium chloride (compound no:15).<br>
1 -(2-(4-nitrothien-2-yl)-2-oxoethyl)-3 -(methane sulfonyl hydrazino<br>
carbonyl) pyridinium bromide, (compound no;16").<br>
1-(2-phenylamino-2-oxoethyl)-3-(phenyl hydrazino carbonyl)<br>
pyridinium chloride (compound no: 11).<br>
1-(2-phenylamino-2-oxoethyl)-4 -[ 2-(benzoyloxy) ethylamino<br>
carbonyl ] pyridinium chloride (compound no: 18").<br>
1 -2-(5-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl) pyridinium chloride (compound no: .19).<br>
1 -(2-thien-2"-yl-2-oxoethyl)-3-(trifluoromethanesulfonyl hydrazino<br>
carbonyl) - pyridinium bromide, (compound no. 20,).<br>
1-(2-thien-2"-yl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium<br>
bromide (compound no.21).<br>
1-(2-thien-2"-yl-2-oxocthyl)-3-(p-methoxy phenyl sulfonyl hydrazino<br>
carbonyl) pyridinium bromide (compound no. 22).<br>
1-(2-ethoxy-2-oxoethyl)-3-(phenyl aminocarbonyl hydrazino carbonyl)<br>
pyridinium bromide (compound no. 23).<br>
1-(2-ethoxy-2-oxoemyl)-3-(p-toluene sulfonyl hydrazino carbonyl)<br>
pyridinium bromide (compound no. 24).<br>
1-(2-phenyl-2-oxoethyl)-3-(phenylamino carbonyl hydrazino carbonyl)<br>
pyridinium bromide (compound no. 25).<br>
1 -(2-phenylamino-2-oxoethyl)-3-(benzyl sulfonyl hydrazino carbonyl)<br>
pyridinrumchloride. (compound no. 26 ).<br>
1-(2-phenyl-2-oxoethyl)-4-(methanesulfonyl hydrazino carbonyl)<br>
pyridinium bromide (compound no. 27).<br>
1-(2-phenyl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium<br>
bromide, (compound no. 28).<br>
1-(2-ethoxy-2-oxoethyl)-4-[2-(benzoyloxy) ethyl amino carbonyl ]<br>
pyridinium bromide (compound no. 29 ).<br>
1-(2-ethoxy-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium<br>
bromide.(compound no.3o ).<br>
1-(2-phenyl-2-oxoethyl)-3-(p-methoxyphenyl sulfonyl hydrazino<br>
carbonyl) pyridinium bromide, (compound no. 31).<br>
1-(2-phenyl-2-oxoethyl)- 4-[2-(benzoyloxy) ethyl amino carbonyl ]<br>
pyridinium bromide, (compound no.32.).<br>
1-(2-ethoxy-2-oxoethyl)- 4-(p-methanesulfonyl hydrazino carbonyl )<br>
pyridinium bromide, (compound no. 33).<br>
In place of specific halide salts of the compounds listed above,<br>
these compounds may also be in the form of other pharmaceutically<br>
acceptable salts falling within the definition of X as given above. The<br>
words "and pharmaceutically acceptable salts thereof as used herein<br>
following the names of specific compounds of general formula (I) of the<br>
invention means that such compounds encompass other<br>
pharmaceutically acceptable salts falling within the definition of X.<br>
According to the embodiment of the present invention, the<br>
present compounds are used for the treatment of diabetic<br>
complications, and aging related vascular and neurovascular<br>
complications including kidney disease, nerve damage, atherosclerosis,<br>
retinopathy, inflammatory discorders, immunological disorders,<br>
oxidative stress, dermatological conditions, and cosmetic conditions<br>
including colouration of teeth occurring due to the higher levels of<br>
preformed AGE. The increased levels of preformed AGE can be<br>
brought under control by breaking the AGE products using compounds<br>
mentioned in the invention.<br>
The invention also provides a process for the preparation of<br>
novel compounds of the pyridinium series.<br>
The novel compounds of general formula I, are<br>
prepared from properly substituted pyridine derivatives followed by<br>
quarternization with appropriate reagent by refluxing in alcoholic<br>
solvents like, methanol, ethanol, propanol, etc and high boiling solvents<br>
like toluene or xylene etc, for 6-48 hrs. to give the desired<br>
compounds.<br>
The examples of substituted pyridine derivatives which can be<br>
used for preparation of specific compounds of the invention are given<br>
below:<br>
1. N,N"-bis(nicotinyl)hydrazine<br>
2. 3-[(2-pyridyl)hydrazinocarbonyl]pyridine<br>
3. 3-[2-methanesulfonyl)hydrazinocarbonyl]pyridine<br>
4. 3-[(2-benzoyloxy)ethylamiiiocarbonyl]pyridine<br>
5. 3-[(2-phenylsulfonyl)hydrazinocarbonyl] pyridine<br>
6. 3-[(2-acetoxy)ethyloxycarbonyl]pyridine<br>
7. 3-[(2-benzoyloxy)ethyloxycarbonyl]pyridine<br>
8. 3-[(2-methoxy)ethyloxycarbonyl]pyridine<br>
9. 3-[(2-phenylaminocarbonyl)hydrazinocarbonyl]pyridine<br>
10. 3-[(2-acetoxy)ethylaminocarbonyl]pyridine<br>
11. 3-[(2-(4-methylphenyl sulfonylhydrazinocarbonyl))]pyridine<br>
12. 3-[(2-benzoyl)- hydrazino carbonyl]pyridine<br>
13. 3-[(2-phenyhnethane sulfonyl) hydrazino carbonyl] pyridine<br>
14. 3-[(2-(3-cyclohexylpropanoyl) hydrazino carbonyl]pyridine<br>
15. 3-[(2-methoxy)ethylaniinocarbonyllpyridine<br>
16. 3-[l-oxo-1 -(2-methoxycarbonyl)pyridyl Jhydrazine pyridine<br>
The examples of quaternizing agents which may be used in the reaction are given below:<br>
1. 2-bromoacetyl thiophene<br>
2. 2-chloroacetyl thiopene<br>
3. phenacylbromide<br>
4. phenacyl chloride<br>
5. 2,4-dichllrophenacylbromide<br>
6. N-phenyl chloroacetamide<br>
7. N-cyclopropyl chloroacetamide<br>
8. ethylbromoacetate<br>
9. bromo acetylfuran<br>
10. N-isopropyl chloroacetamide<br>
11. N-chloroacetyl-2-pyrrolidinone<br>
12. chloroacetic acid<br>
In-vitro screening for AGE-breaking Activity<br>
The in vitro AGE formation, studied in the laboratory, by incubating reducing<br>
sugar glucose, with protein bovine serum albumin, resulted in browning of solution and<br>
increase in the fluorescence. Fluorescence was used as the criteria to monitor the<br>
increased AGE formation.<br>
Example 1<br>
AGE breaker activity has been confirmed by the screening<br>
procedure as mentioned below:<br>
Materials:<br>
Bovine serum albumin (fraction V) (BSA)<br>
Glucose, analytical grade<br>
Phosphate buffered saline (PBS)<br>
Equipment:<br>
Microplate ELISA Reader - Spectramax Plus (Molecular Devices,<br>
USA)<br>
Microplate washer, (Bio -Tec Instruments, USA)<br>
pH meter<br>
Methods of experiment: Elisa (Enzyme Linked Immunosorbent Assay)<br>
160 mg/ml of protein, bovine serum albumin, BSA and 1.6M<br>
glucose sugar were dissolved in phosphate buffered saline, PBS.<br>
Sodium azide was added at 0.02% concentration as a preservative. The<br>
solution was filtered asceptically through a 0.22 µM filter and kept for<br>
aging at 37°C for 16 weeks. After 16 weeks the solution was dialyzed<br>
against PBS, aliquoted and stored at - 20°C.<br>
To determine the AGE breaking activity, 10µg/ml of the 16<br>
weeks AGE-BSA was incubated with different concentrations of the<br>
test compounds at 37°C for 24 hours and AGE breaking activity of the<br>
test compounds by ELISA was determined.<br>
ELISA was performed as follows:<br>
1. Different concentrations of 16 weeks AGE-BSA were coated on a<br>
microtitre plate as standard. Each concentration is coated in triplicates.<br>
2. The test samples were coated on microtitre plate at a concentration<br>
of 5 ng. to 20 ng per well in triplicates.<br>
3. The plate was incubated at 37°C for one hour.<br>
4. After incubation the plate was washed with PBST (PBS with 0.05%<br>
Tween 20).<br>
5. Blocking with 5% skimmed milk in PBS at 37°C for one hour was<br>
done.<br>
6. The plate was washed with PBST.<br>
7. Primary antibody against AGE-BSA was added and the plate is<br>
incubated at 37°C for one hour.<br>
8. The plate was washed with PBST<br>
9. Secondary antibody anti rabbit HRPO (Horse-Radish Per Oxidase)<br>
conjugate was added and the plate is incubated at 37°C for one hour.<br>
10. The plate was washed with PBST.<br>
11. Colour development with OPD (orthophenylenediamine<br>
dihydrochloride) and hydrogen peroxide was done.<br>
12. OD (optical density) at (450nm reading - 620nm reading) was<br>
measured after incubation at 37°C for 15 minutes with Microplate<br>
ELISA Reader.<br>
The breaker activity of the compounds were determined by the<br>
following formula:<br><br>
OD450-620Control= Absorbance of 20ng AGE-BSA after incubation at<br>
37°C for 24 hours without test compound<br>
OD450-620Test= Absorbance of 20ng AGE-BSA after incubation at 37°C<br>
for 24 hours with required concentration of test compound<br>
Using specific examples, the % AGE breaking activity was calculated<br>
and recorded in Table 2.<br>
Hence compounds -1,2,5-10,12,14,16,17,19<br>
and 20 have superior AGE breaking activity compared to PTB, of<br>
which the potency of compounds .1,8-10,12,14,16,17,19 and 20<br>
are significantly much higher.<br>
The following examples give method of preparation of the<br>
specific novel compounds of the invention as given in Table 1. The<br>
following compounds suggested are by way of example alone and in no<br>
way restrict the invention.<br>
Example 2.<br>
1-[1-(2-Thien-2"-yl-2-oxoethvI)-6methyl-3-carbonvl pvridiniumj-2-<br>
[1-(2-Thien-2"-yl-2-oxoethvl )-3--carbonvl pyridinium ] hvdrazine<br>
dichloridefcompound no: 1 ),<br>
Yield " : 40%<br>
M.P. : 76-80 °C (dec)<br>
IR(KBr,cm-1) : 1637,1513<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.69(2H,s), 9.59-<br>
9.53(2H,d), 9.19(2H,m), 9.05(lH,d), 8.46-8.43(1H,t) ,8.34(lH,d), 8.27-<br>
8.23(4H,m), 7.45-7.41 (2H,ra) ,6.56(2H,s) ,6.48(2H,s),2.81(3H,s).<br>
Mass(m/z) : 505,506,507.<br>
Example 3<br>
1-(2-Thien-2"-vl-2-oxoethvl)-3-(isopropvlsulfonvI hvdrazino<br>
carbonvl) pyridinium bromide(compound no: 2.),<br>
Yield . : 70%<br>
M.P : 90-95°C (dec)<br>
IR(KBr.cm-1) 1638,1589<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11 .27(1H,s) ,9.91(1H,s),<br>
9.60(1H,s) ,9.19-9.15(2H5m), 8.42-8.36(1 H,m) ,8.25-8.21(2H,m) ,7.43-<br>
7.41(1H,t) ,6.45(2H,s), 1.35-1.34(6H,d).<br>
Mass(m/z) : 368,369,370<br>
Example 4-<br>
1-(2-(4-Benzvl piperidin-l-vl)-2-oxoethvl)-3-(methanesulfonvl<br>
hvdrazino carbonvl) pyridinium chloride(compound no: 3.),<br>
Yield : 17%<br>
M.P : 76-78°C<br>
IR (KBr,cm-1) : 1684,1650,1556,1540.<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.46(1H,s) ,9.55(1H,s),<br>
9.46(1H,s) ,9.09-9.03(2H,m), 8.36-8.32(1H,t), 7.33-7.29(2H,m), 7.23-<br>
7.19(3H,m), 5.88-5.79(2H,m) ,4.30-4.27(1H,d) ,3.76-3.73(1H,d),<br>
3.10(4H,m) ,2.64(1H,t) ,2.57-2.55(2H,d), 1.85(1H,bs) ,1.72-<br>
1.63(2H,t),1.36-1.28(1H,q) ,1.13-1.03(1H,m)<br>
Mass(m/z) : 431,432,433<br>
Example S<br>
1-(2-(2-Ethoxv carbonvl pvrrolidin-l-vl)-2-oxoethvl)-3-<br>
(methanesulfonvl hydrazino carbonvl) pvridinium chloride,<br>
(compound no: 4 ),<br>
Yield : 14%<br>
M.P : 88-91°C<br>
IR(KBr,cm1) : 1735,1665,1539<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.48(1H,s) ,9.96(1H,s)<br>
,9.46(1H,s) ,9.09-9.05(2H,m) ,8.38-8.34(1H,t), 5.94-5.80(2H,q) ,4.37-<br>
4.36(1H,d), 4.08-4.06(2H,d), 3.68-3.65(2H,m), 3.09(4H,m) ,2.23-<br>
2.18(2H,m), 2.04 -1.93(3H,m) ,1.18-1.09(3H,t)<br>
Mass(m/z) : 399,400,401<br>
Example 6<br>
1-(2-Thien-2"-vl~2-oxoethvI)-3-(methanesulfonyl hydrazino<br>
carbonyl )-5-bromo pvridinium bromide, (compound no: 5.),<br>
Yield : 54%<br>
M.P : Above 190-195 °C(dec)<br>
IR(KB,cm-1) : 1682,1557,1540,1520<br>
1HNMR (DMSO d6, 400 MHz) 8 : 11.35(1H,s) ,10.01(1H,s)<br>
,9.57-9.54(2H,d), 9.32(1H,s), 8.26-8.22(2H,m),7.42(1H,s),6.39(2H,s),<br>
3.08(3H,s)<br>
Mass(m/z) : 418,419,420<br>
Example .7-<br>
1-(2-Thien-2"-yl-2-oxoethyl)-3-(ethoxvcarbonvI hvdrazino carbonvl)<br>
pvridinium bromide, (compound no: 6 ),<br>
Yield : 69%<br>
M.P : 155-157°C<br>
IR(KBr,cm-1) : 1731,1665,1637<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.04(1H,s), 9.59(1H,s) ,<br>
9.53(1H,s), 9.18(1H,s), 9.05-9.04(1H,d), 8.42(1H,s), 8.25-<br>
8.23(2H,m), 7.43(1H,s), 6.46(2H,s), 4.12-4.11(2H,s), 1.23(3H,s)<br>
Mass (m/z) : 334,335,336<br>
Example .8<br>
1-(2-(5-chloro-thien-2-yI)-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl) pyridinium bromide (compound no: 7-)<br>
Yield : 87%<br>
M.P : 228-230°C<br>
IR (KBr,cm-1) : 1708,1664,1631,1550<br>
"HNMR (DMSO d6, 400 MHz) 5 : 11.40(1H,s), 9.98(1H,s),<br>
9.50(1H,s), 9.15(1H,d) , 9.061H,d), 8.43-8.39(1H,t), 8.16-8.15(1H,d),<br>
7.51-7.50(1 H,d), 6.41 (2H,s), 3.09 (3H,s)<br>
Mass (m/z) : 374,375,376,377<br>
Example .9<br>
N-N"-Bis[3-carbonyl-1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)pvridinium]<br>
hvdrazine dichloride. (compound no: .8 ),<br>
Yield : 27%<br>
M.P : 204-207°C<br>
IR (KBr,cm-1) : 1681,1539,1514<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.90(2H,s), 9.63(2H,s),<br>
9.31-9.30(4H,m), 9.24 -9.22(2H,m), 8.87(2H,s), 8.49-8.46(2H,t), 6.56<br>
(4H,s)<br>
Mass (m/z) : 581,582,583<br>
Example 10<br>
1-(2-Thien-2"-yl-2-oxoethyl-3-(methanesulfonyl hydrazino carbonyl)<br>
-6-methyl pyridinium bromide, (compound no:9 ),<br>
Yield : 14%<br>
M.P : 90-95°C(dec)<br>
IR (KBr,crn1) : 1677,1575<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.32(1H,s),<br>
9.97(1H,s) 9.52(1H,s), 8.94-8.92(1H,d) , 8.32-8.24(3H,m),<br>
7.44(1H,t), 6.54(2H,s), 3.08(3H,s), 2.79(3H,s)<br>
Mass (m/z) : 354,355,356<br>
Example 11<br>
N-N"-Bis[3-carbonyl-1-(2-(5-methvl-thien-2-vl)-2-oxoethvn<br>
pvridiniuml hydrazine dichloride. (compound no: 10),<br>
Yield : 37%<br>
M.P : Above 166-168°C(dec)<br>
IR(KBr,cm-1) : 1666,1500<br>
1HNMR (DMSO 4, 400 MHz) 5 : 11.73(2H,s), 9.59(2H,s),<br>
9.19-9.15(4H,d) 8.45-8.42(2H,t), 8.06-8.05(2H,d) ,7.15-7.14(2H,d),<br>
6.43 (4H,s), 2.59(6H,s)<br>
Mass(m/z) : 519,520,521,522<br>
Example 12<br>
N-N"-Bis [3-carbonvl-1 -(2-(2-ethoxy carbonvl pyrrolidin-1 -yl)-2-<br>
oxoethvl) pvridiniuml hvdrazine dichloride. (compound no: 11),<br>
Yield : 28%<br>
M.P : 118-120°C<br>
IR (KBr,cm-1) : 1660,1510<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.75(2H,s), 9.51(2H,s),<br>
9.20-9.10(4H,m) 8.43-8.40(2H,t), 5.97-5.83(4H,m) ,4.39-4.36(2H,m),<br>
4.27-4.22(1H,q), 4.12-4.05(4H,m), 3.71-3.63(4H,m), 3.48-3.40(1H,m),<br>
2.26-2.19(2H,m),2.05-1.91(5H,m), 1.30-1.27(1H,t), 1.19-1.15(5H,t)<br>
Mass(m/z) : 609,610,611<br>
Example 13<br>
l-[1-(2-Thien-2"-vl-2-oxoethvl)-5-aminocarbonyl-3-carbonvl<br>
pyridiniuml-2-f1-(2-Thien-2"-vl-2-oxoethyl )-3-carbonvl pvridiniuml<br>
hvdrazine dichloride (compound no: 12)<br>
Yield : 54%<br>
M.P : Above 127-129°C(dec)<br>
IR (KBr,cm-1) : 1678,1513<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.86(2H,s), 9.83-<br>
9.64(4H,t), 9.24 -9.23(2H,s), 8.82(1H,s), 8.48-8.45(1 H,t), 8.34(1H,s)<br>
8.26-8.24(4H,m), 7.44 -7.42(2H,d), 6.52-6.46(4H,d)<br>
Mass (m/z) : 534,535,536<br>
Example 14<br>
1-(2-(4-carbethoxv-thiazolidin-3vl)-2--oxoethvl)-3-(methanesulfonyl<br>
hvdrazino carbonvl) pyridinium chloride (compound no: 13),<br>
Yield : 29%<br>
M.P : 190-192°C<br>
IR(KBr,cm-1) : 1673,1541<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.50(1H,s), 9.55(1H,s),<br>
9.48(1H,s), 9.12-9.08(2H,m), 8.39-8.34(1H,t), 6.04 - 5.99(2H,m) ,<br>
4.94 -4.91(1H,m), 4.87-4.84(1H,d), 4.73-4.71(1H,d), 4.28-4.23(1H,q),<br>
4.14 -4.09(1H,q), 3.43-3.38(1H,m),3.27-3.22(1H,m), 3.10(3H,s) ,1.30-<br>
1.27(1H,t), 1.20-1.17(2H,m)<br>
Mass(m/z) : " 439,440,441<br>
Example 15<br>
N-N"-Bis[3-carbonvl-1-(2-(S-chIoro-thien-2-vn-2-oxoethvl)<br>
pyridinium] hydrazine dichloride. (compound no: 14:),<br>
Yield : 35%<br>
M.P : Above 200-205°C (dec)<br>
IR(KBr,cm-1) : 1674,1590,1500<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.90(2H,s), 9.64 -<br>
9.61(2H,d), 9.29-9.20(4H,m) , 8.47-8.44(2H,t), 8.18-8.17(2H,d),7.51-<br>
7.50(2H,d),6.49-6.48(4H,s)<br>
Mass(m/z) : 559,560,561,562,563,564<br>
Example 16<br>
1-(2-(5-Methyl-thien-2-vn-2-oxoethvl)-3-(methanesulfonyl<br>
hydrazino carbonvl) pyridinium chloride (compound no: 15),<br>
Yield : 22%<br>
M.P : 196-198°C<br>
IR(KBr,cm-1) : 1689,1657<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.47(1H,s) ,9.98(1H,s)<br>
,9.53(1H,s) ,9.17-9.16(1H,d), 9.09-9.07(1H,d), 8.42-8.38(1H,t), 8.06-<br>
8.05(1H,d), 7.15-7.14(1H,d), 6.41 (2H,s), 3.09(3H,s), 2.59(3H,s)<br>
Mass(m/z) : 354,355,356,357<br>
Example 17<br>
1-(2-(4-Nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonvl hydrazino<br>
carbonvl) pyridinium bromide, (compound no: 16).<br>
Yield : 52%<br>
M.P : Above 200-205°C(dec)<br>
IR(KBr,cm-1) : 1688,1631,1541<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.41(1H,s), 9.50(1H,s)<br>
9.309-9.306(1H,d), 9.17-9.15(1H,d) ,9.09-9.07(1H,d), 8.866-<br>
8.862(1H,d) ,8.45-8.41(1H,t), 6.50(2H,s), 3.09(3H,s)<br>
Mass(m/z) : 385,386,387<br>
Example 18<br>
1-(2-Phenylamino-2-oxoethyI)-3-(Phenyl hydrazino carbonyl)<br>
pyridinium chloride (compound no: 17),<br>
Yield : 45%<br>
M.P : 165-167°C<br>
IR(KBr,cm-1) : 1679,1626,1600,1497<br>
1HNMR (DMSO d6, 400 MHz) 8 : 11.18(1H,s), 11.10(1H,s)<br>
, 9.62(1H,s) , 9.24-9.22(1H,d), 9.17-9.15(1H,d), 8.40-8.36(1H,t),<br>
8.19(1H,s), 7.63-7.61(2H,d) , 7.37-7.33(2H,t), 7.20-7.16(2H,t), 7.12-<br>
7.09(1H,t), 6.88-6.86(2H,d), 6.78-6.74(1H,t) , 5.78(2H,s)<br>
Mass(m/z) : 347,348,349<br>
Example 19<br>
1-(2-Phenvlamino-2-oxoethyl)-4 -I 2-(benzovIoxy) ethylamino<br>
carbonvl] pyridinium chloride (compound no: 18),<br>
Yield : 40%<br>
M.P : 178-180°C<br>
IR (KBr,cm-1) : 1700,1666,1559<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.13(1H,s), 9.74 -<br>
9.71(1H,t), 9.23-9.22(2H,d), 8.52-8.50(2H,d), 8.01-7.99(2H,d),<br>
7.68-7.60(3H,m) , 7.54-7.5l(2H,t), 7.36-7.32(2H,t), 7.12-7.08 (1H,t),<br>
5.75 (2H,s), 4.47-4.45(2H,t), 3.77-3.72(2H,q).<br>
Mass (m/z) : 404,405,406<br>
Example 20<br>
l-2-(5-Nitro-thien-2-yl-2-oxoethvI)-3-(methanesulfonyl hydrazino<br>
carbonvl) pyridinium chloride (compound no: 19),<br>
Yield : 10%<br>
M.P : Above 105-110°C(dec)<br>
IR(KBr,cm-1) : 1680,1620<br>
"HNMR (DMSO d6, 400 MHz) 5 : 11.48(1H,s), 9.98(l.H,s),<br>
9.52(1H,s), 9.16-9.10(2H,m) ,8.45-8.41(1H,t) , 8.35-8.34(1H,d) ,8.25-<br>
8.24(1H,d), 6.50(2H,s), 3.09(3H,s).<br>
Mass (m/z) : 385,386,387<br>
Example 31<br>
1-(2-Thien-2"-vl-2-oxoethvI)3-(TrifIuromethanesulfonvl hydrazino<br>
carbonvl)-pyridinium bromide (compound no: 20),<br>
Yield : 22%<br>
M.P : 77-79°C<br>
IR (KBr,cm-1) : 2960, 1690, 1673, 1591<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.76(1H,s),<br>
11.27(1H,s), 9.61(1H,s), 9.20-9.19(1H,d) ,9.07-9.05(1H,d), 8.44-<br>
8.41(1H,t) ,8.25-8.22(2H,m), 7.34 - 7.41 (1H,m), 6.46 (2H,s).<br>
Mass (m/z) : 394,395,396<br>
Example 22<br>
1-(2-Thien-2"-vl-2-oxoethvl)-3-(phenvl hvdrazino carbonvl)<br>
pvridinium bromide (compound no. 21),<br>
Yield : 10%<br>
M.P : 192-194°C<br>
IR(KBr,cm-1) : 1669,1663,1603,<br>
1HNMR (DMSO d6, 400 MHz) 5 : 10.99(1H,s), 9.54(1 H,s),<br>
9.17-9.14(2H,t), 8.44-8.41(1H,t), 8.25-8.22(3H,m), 7.43-7.41(1H,t),<br>
7.20-7.16(2H,t), 6.87-6.85(2H,d) , 6.79-6.75(1H,t), 6.46(2H,s)<br>
Mass(m/z) : 338,339,340<br>
Example 23<br>
1-(2-Thien-2"-vl-2-oxoethvl)-3-(p-methoxy phcnvl sulfonvl<br>
hvdrazino carbonvl) pvridiniuin bromide (compound no. 22.),<br>
Yield : 28%<br>
M.P : 126-]28°C<br>
IR(KBr.cm-1) : 1672,1653,1596<br>
1HNMR (DMSO 4, 400 MHz) 5 : 11.34 -11.33(1H,d),<br>
10.27-10.26(1H,d), 9.34(1H,s), 9.13-9.12(1H,d), 8.94-8.92(1H,d),<br>
8.38-8.34(1H,t) ,8.24-8.19(2H,m),7.82-7.75(2H,m) ,7.42-7.40(1H,t),<br>
7.07-7.04(2H,d) ,6.40(2H,s), 3.81(3H,s).<br>
Mass(m/z) : 432,433,434<br>
Example 24<br>
1-(2-Ethoxv-2-oxoethv))-3-(phenyl aminocarbonvl hvdrazino<br>
carbonvl) pyridinium bromide, (compound no. 23),<br>
Yield : 25%<br>
M.P : 183-185°C<br>
IR(KBr,cm-1) : 1746,1717,1682<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.02(1H,s), 9.57(1H,s),<br>
9.22-9.21(1H,d), 9.11-9.09(1H,d), 9.00(1H,s), 8.57(1H,s) ,8.44-<br>
8.41(1H,m),7.47-7.45(2H,d) ,7.29-7.25(2H,t), 7.00-6.96(1H,t),<br>
5.74(2H,s), 4.28-4.23(2H,q), 1.28-1.25(3H,t).<br>
Mass(m/z) : 343,344,345,346<br>
Example 25<br>
1-(2-Ethoxv-2-oxoethyl)-3-(p-toluene sulfonvl hvdrazino carbonvl)<br>
pvridinium bromide, (compound no. 24-),<br>
Yield : 54%<br>
M.P : 174-176°C<br>
IR(KBr,cm-1) : 1746,1712,1634<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.33(1H,s),<br>
10.36(1H,s), 9.37(1H,s), 9.18-9.16(1H,d), 8.93-8.91(1H,d), 8.37-<br>
8.33(1H,t), 7.78-7.76(2H,d), 7.37-7.35(2H,d), 5.68 (2H,s), 4.26-<br>
4.20(2H,q),2.37(3H,s),1.27-1.23(3H,t).<br>
Mass(m/z) : 378,379,380,381<br>
Example 36<br>
1-(2-Phenvl-2-oxoethvl)-3-(Phenylamino carbonyl hydrazino<br>
carbonvl) pyridinium bromide, (compound no.25),<br>
Yield : 70%<br>
M.P : 206-208°C<br>
IR(KBr,cm-1) : 1713,1684,1634<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.05(1H,s), 9.55(1H,s),<br>
9.18-9.13(2H,m), 9.02(1H,s), 8.59(1H,s), 8.49-8.45(1H,m) ,8.09-<br>
8.07(2H,d), 7.84-7.80(1H,t) , 7.71-7.67(2H,t), 7.49-7.47(2H,d), 7.30-<br>
7.26(2H,t), 7.01-6.97 (1H,t) ,6.56(2H,s).<br>
Mass (m/z) : 375,376,377<br>
Example 27<br>
1-(2-Phenylamino-2-oxoethvI)-3-(benzvI sulfonyl hydrazino<br>
carbonvl) pyridiniumchloride. (compound no.26),<br>
Yield : 48%<br>
M.P : 208-210°C<br>
IR(KBr,cm-1) : 1712,1681,1632<br>
1HNMR (DMSO d6, 400 MHz) 8 : 11.46(1H,s) ,10.80(1H,s),<br>
9.59(1H,s), 9.22-9.20(1H,d) ,9.08-9.06(1H,d), 8.38-8.36(1H,t),7.60-<br>
7.58(2H,d) ,7.49(2Hsm), 7.39-7.34(5H,m),7.13-7.10(1 H,t),<br>
5.74(2H,s), 4.52(2H,s).<br>
Mass(m/z) : 425,426,427,428<br>
Example 28<br>
1-(2-Phenyl-2-oxoethyl)-4-(methanesulfonvl hvdrazino carbonyl)<br>
pyridinium bromide (compound no. 27),<br>
Yield : 10%<br>
M.P : 190-192°C<br>
IR(KBr,cm-1) : 1679,1630,1650<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.54(1H,s), 10.03(1H,s),<br>
9.20-9.18(2H,d), 8.59-8.57(2H,d), 8.10-8.08(2H,d), 7.84 -7.80(1H,t),<br>
7.71-7.67(2H,t), 6.56(2H,s), 3.08(3H,s).<br>
Mass(m/z) : 334,335,336<br>
Example 2S<br>
1-(2-PhenvI-2-oxoethyl)-3-(phenyl hvdrazino carbonvl) pvridinium<br>
bromide (compound no."28"),<br>
Yield : 36%<br>
M.P : 204-206°C<br>
IR(KBr,cm-1) : 1686,1653,1630<br>
1HNMR (DMSO d6, 400 MHz) 6 : 11.01(1H,s) ,9.53(1H,s)<br>
,9.17-9.16(2H,m), 8.46-8.42(1H,t), 8.09-8.07(2H,d), 7.82-7.78(1 H,t),<br>
7.69-7.65(2H,t), 7.20-7.16(2H,t), 6.88-6.86(2H,d), 6.79-6.75(1H,t),<br>
6.56(2H,s)<br>
Mass(m/z) : 332,333<br>
Example 30<br>
1-(2-Ethoxv-2-oxoethyl)-4-[2-(benzovIoxv) ethyl amino carbonvl ]<br>
pvridinium bromide (compound no.29),<br>
Yield : 82%<br>
M.P : 154-156°C<br>
IR(KBr,cm-1) : 1742,1719,1707,1675<br>
1HNMR (DMSO d6, 400 MHz) 5 : 9.57-9.54(1H,t), 9.22-<br>
9.20(2H,d), 8.51-8.49(2H,d), 8.00-7.98(2H,d), 7.68-7.64(1H,t), 7.54<br>
-7.51(2H,t), 5.72(2H,s), 4.47-4.44(2H,t), 4.27-4.21(2H,q), 3.76-<br>
3.72(2H,q), 1.27-1.24. (3H,t)<br>
Mass(m/z) : 357,358,359.<br>
Example 31<br>
1-(2-Ethoxv-2-oxoethyl)-3-(phenvl hvdrazino carbonvl) pvridinium<br>
bromide.(compound no. 30),<br>
Yield : 37%<br>
M.P : 185-187°C<br>
IR (KBr,cm-1) : 1740,1690,1630.<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.01(1H,s), 9.58(1H,s),<br>
9.23-9.14(2H,m), 8.42-8.39(1H,t), 8.19(1H,s), 7.20-7.16(2H,t), 6.87-<br>
6.85(2H,d), 6.78-6.75(1H,t), 5.75(2H,s), 4.28-4.22(2H,q), 1.28-1.24(3H,t)<br>
Mass(m/z) : 300,301,302.<br>
Example 32.<br>
1-(2-PhenvI-2-oxoethvl)-3-(p-methoxvphenvl sulfonvl hydrazino<br>
carbonvl) pvridinium bromide (compound no. 31),<br>
Yield : 59%<br>
M.P : 188-190°C<br>
IR(KBr,cm-1) : 1671,1634,1580.<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.26-11.25(1H,d),<br>
10.17- 10.16(1H,d), 9.24(1H,s), 9.03-9.01(1H,d), 8.87-8.85(1H,d) ,<br>
8.31-8.27(1H,t), 7.97-7.96(2H,d), 7.74 -7.69(3H,m), 7.60-7.56(2H,t)<br>
, 6.99-6.97(2H,d), 6.40(2H,s), 3.73(3H,s).<br>
Mass(m/z) : 426,427,428,429<br>
Example 33<br>
1-(2-Phenvl-2-oxoethvl)- 4-[2-(benzovloxv) ethyl amino carbonvl ]<br>
pvridinium bromide (compound no.32),<br>
Yield : 92%<br>
M.P : 202-204°C<br>
IR(KBr,cm-1) : 1715,1692,1650<br>
1HNMR (DMSO d6, 400 MHz) 5 : 9.55(1H,s), 9.14-<br>
9.13(2H,d), 8.52-8.51(2H,d), 8.07-7.99(4H,m), 7.80-7.51(6H,m),<br>
6.52(2H,s), 4.46(2H,s), 3.76-3.75(2H,s).<br>
Mass(m/z) : 389,390,391,392<br>
Example 34-<br>
1-(2-Ethoxy-2-oxoethyl)- 4-(p-methanesulfonyl hvdrazino carbonvl)<br>
pvridinium bromide, (compound no. 33),<br>
Yield . : 45%<br>
M.P : 94-96°C<br>
IR(KBr,cm-1) : 1726,1681,1643<br>
1HNMR (DMSO d6, 400 MHz) 5 : 11.49(1H,s) ,9.98(1 H,s)<br>
,9.23-9.21(2H,d), 8.54-8.52(2H,d), 5.73(2H,s), 4.28-4.22(2H,q),<br>
3.09(3H,s), 1.28-1.25(3H,t).<br>
Mass(nVz) : 302,303,304,305.<br>
Pharmaceutical Compositions<br>
Pharmaceutical compositions may be prepared with a<br>
pharmaceutically effective quantity of compounds of general formula I,<br>
individually or in combination. The following pharmaceutical<br>
formulations suggested are by way of example alone and in no way<br>
restrict the forms in which they can be used.<br>
Oral formulations<br>
Oral formulations may be administered as solid dosage forms for<br>
example pellets, powders, sachets or discreet units such as tablets or<br>
capsules and like. Other orally administered pharmaceutical<br>
preparations include monophasic and biphasic liquid dosage forms<br>
either in ready to use form or forms suitable for reconstirution such as<br>
mixtures, syrups, suspensions or emulsions. The preparations in<br>
addition may contain diluents, dispersing agents, buffers, stabilizers,<br>
solubilizers, surfactants, preservatives, chelating agents and/ or other<br>
pharmaceutical additives as are used. Aqueous or non aqueous vehicle<br>
or their combination may be used and if desired may contain suitable<br>
sweetener, flavoring agent or similar substances. In case of suspension<br>
or emulsion a suitable thickening agent or suspending agent or<br>
emulsifying agent may be present in addition. Alternatively, the<br>
compounds may be administered as such in their pure form<br>
unassociated with other additives for example as capsules or sachets. It<br>
may also be administered with a vehicle. Pharmaceutical preparations<br>
can have a slow, delayed or controlled release of active ingredients as<br>
is provided by a matrix or diffusion controlled system.<br>
When the present invention or its salts or suitable complexes is<br>
presented as a discreet unit dosage form like tablet, it may contain in<br>
addition medically inert excipients as are used in the art. Diluents such<br>
as starch, lactose, dicalcium phosphate, talc, magnesium stearate,<br>
polymeric substances like methyl cellulose, fatty acids and derivatives,<br>
sodium starch glycollate, etc. may also be used.<br>
Example 35<br>
Preparation of oral dosage form:<br>
A typical tablet has the following composition:<br>
Active ingredient of formula I as given above<br>
Lactose 135 mg<br>
Starch 76 mg<br>
Polyvinyl pyrolidone (K-30) 2 mg<br>
Talc 1-5 mg<br>
Magnesium Stearate 1.0 mg<br>
Parenteral Formulations<br>
For parenteral administration, the compounds or their salts or<br>
suitable complexes thereof may be present in a sterile vehicle which<br>
may be an aqueous or non aqueous vehicle or a combination thereof.<br>
The examples of vehicles are water, ethyl oleate, oils and derivatives of<br>
polyols, glycols and their derivatives. It may contain additives common<br>
in injectable preparations like stabilizers, solubilizers, pH modifiers,<br>
buffers, antioxidants, cosolvents, complexing agents, tonicity modifiers,<br>
etc.<br>
Some suitable additives are for example tartrate, citrate or<br>
similar buffers, alcohol, sodium chloride, dextrose and high molecular<br>
weight polymers. Another alternative is sterile powder reconstitution.<br>
The compound may be administered in the form of injection for more<br>
than once daily administration, or intravenous infusion/ drip or suitable<br>
depot preparation.<br>
Example 36<br>
Preparation suitable for parenteral administration has the<br>
following composition:<br>
Active ingredient of formula I as given above<br>
Polyethylene glycol (400) 0.75 ml<br>
Sodium metabisulphite 0.01 %<br>
Isotonic saline/ WFI q.s.<br>
Other Formulations.<br>
For the dermatological application and for the discoloration of<br>
teeth, the recommended formulations are lotions, oral rinse and<br>
toothpaste containing appropriate amount of the compounds of the<br>
general formula I.<br>
The above examples are presented by way of illustration alone<br>
and in no way limit the scope of the invention.<br>
WE CLAIM:<br>
1. A Compound " which is selected from the<br>
group consisting of the following compounds:<br>
(^)l-[1-(2-thien-2"-yl-2-oxoethyl)-5-aminocarbonyl-3-carbonyl<br>
pyridinium]-2-[1-(2-thien-2"-yl-2-oxoethyl )-3-carbonyl pyridinium]<br>
hydrazine dichloride and pharmaceutically acceptable salts thereof,<br>
( b) 1 -(2-thien-2"-yl-2-oxoethyl)-3-(trifluoromethanesulfonyl hydrazino<br>
carbonyl) - pyridinium bromide and pharmaceutically acceptable salts<br>
thereof,<br>
(c)l-[1-(2-thien-2"-yl-2-oxoethyl)-6-methyl-3-carbonyl pyridinium]-2-<br>
[1-(2-thien-2"-yl-2-oxoethyl )-3-carbonyl pyridinium ] hydrazine<br>
dichloride and pharmaceutically acceptable salts thereof,<br>
(dd) N,N"-bis[3-carbonyl-1-(2-(5-methyl-thien-2-yl)-2-oxoethyl)<br>
pyridinium] hydrazine dichloride and pharmaceutically acceptable salts<br>
thereof,<br>
(e) N,N"-bis[3-carbonyl-1-(2-(5-chloro-thien-2-yl)-2-oxoethyl)<br>
pyridinium] hydrazine dichloride and pharmaceutically acceptable salts<br>
thereof,<br>
(f ) 1-(2-tm"en-2"-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl )-6-methyl pyridinium bromide and pharmaceutically<br>
acceptable salts thereof,<br>
(9)N,N"-bis[3-carbonyl-1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)pyridinium]<br>
hydrazine dichloride and pharmaceutically acceptable salts thereof,<br>
(h ) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl hydrazino carbonyl)<br>
pyridinium chloride and pharmaceutically acceptable salts thereof,<br>
(i ) 1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl) pyridinium bromide and pharmaceutically acceptable salts<br>
thereof,<br>
(j ) 1-(2-(5-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl<br>
hydrazino carbonyl) pyridinium chloride and pharmaceutically<br>
acceptable salts thereof,<br>
(k.) 1 -(2-(5-chloro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl<br>
hydrazino carbonyl) pyridinium bromide and pharmaceutically<br>
acceptable salts thereof,<br>
(l) 1-(2-thien-2"-yl-2-oxoethyl)-3-(ethoxycarbonyl hydrazino carbonyl)<br>
pyridinium bromide and pharmaceutically acceptable salts thereof,<br>
(m) 1-(2-thien-2"-yl-2-oxoethyl)-3-(isopropylsulfonyl hydrazino<br>
carbonyl) pyridinium bromide and pharmaceutically acceptable salts<br>
thereof,<br>
(ft..) 1-(2-tliien-2"-yl-2-oxoethyl)-3-(metlianesulfonyl hydrazino carbonyl)<br>
-5-bromo pyridinium bromide and pharmaceutically acceptable salts<br>
thereof,<br>
(o ) 1-(2-(2-ethoxy carbonyl pyrrolidin-l-yl)-2-oxoethyl)-3-<br>
(methanesulfonyl hydrazino carbonyl) pyridinium chloride and<br>
pharmaceutically acceptable salts thereof,<br>
(p ) 1-(2-(5-methyl-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino<br>
carbonyl) pyridinium chloride and pharmaceutically acceptable salts<br>
thereof,<br>
(q) 1-(2-(4-carbethoxy-thiazolidin-3-yl)-2-oxoethyl) -3-<br>
(methanesulfonyl hydrazino carbonyl) pyridinium chloride and<br>
pharmaceutically acceptable salts thereof,<br>
(r ) 1-(2-(4-benzyl piperidin-l-yl)-2-oxoethyl)-3-(methanesulfonyl<br>
hydrazino carbonyl) pyridinium chloride and pharmaceutically<br>
acceptable salts thereof,<br>
(s) N,N"-bis[3-carbonyl-1 -(2-(2-ethoxycarbonyl pyrrolidin-1 -yl)-2-<br>
oxoethyl) pyridinium] hydrazine dichloride and pharmaceutically<br>
acceptable salts thereof;<br>
(t ) 1-(2-phenylamino-2-oxoethyl)-4 -[ 2-(benzoyloxy) ethylamino<br>
carbonyl ] pyridinium chloride and pharmaceutically acceptable salts<br>
thereof,<br>
( u) 1-(2-thien-2"-yl-2-oxoethyl)-3-(phenyl hydrazi.no carbonyl) pyridinium<br>
bromide and pharmaceutically acceptable salts thereof,<br>
(v) 1-(2-thien-2"-yl-2-oxoethyl)-3-(p-methoxy phenyl sulfonyl<br>
hydrazino carbonyl) pyridinium bromide and phannaceutically<br>
acceptable salts thereof,<br>
(W) 1-(2-ethoxy-2-oxoethyl)-3-(phenyl aminocarbonyl hydrazino<br>
carbonyl) pyridinium bromide and phannaceutically acceptable salts<br>
thereof,<br>
(X .) 1-(2-ethoxy-2-oxoethyl)-3-(p-toluene sulfonyl hydrazino carbonyl)<br>
pyridinium bromide and phannaceutically acceptable salts thereof,<br>
(y) 1-(2-phenyl-2-oxoethyl)-3-(phenylamino carbonyl hydrazino<br>
carbonyl) pyridinium bromide and pharmaceutically acceptable salts<br>
thereof,<br>
(z ) 1-(2-phenylamino-2-oxoethyl)-3-(benzyl sulfonyl hydrazino<br>
carbonyl) pyridiniumchloride and pharmaceutically acceptable salts<br>
thereof,<br>
(za.) 1-(2-phenyl-2-oxoethyl)-4-(methanesulfonyl hydrazino carbonyl)<br>
pyridinium bromide and phannaceutically acceptable salts thereof,<br>
(zb) 1-(2-phenyl-2-oxoethyl)-3-(phenyl hydrazino carbonyl)<br>
pyridinium bromide and pharmaceutically acceptable salts thereof,<br>
(zc) 1 -(2-ethoxy-2-oxoethyl)-4-[2-(benzoyloxy) ethyl ammo carbonyl ]<br>
pyridinium bromide and pharmaceutically acceptable salts thereof,<br>
(Zd) 1-(2-ethoxy-2-oxoethyl)-3-(phenyl hydrazino carbonyl)<br>
pyridinium bromide and pharmaceutically acceptable salts thereof,<br>
(ze) 1-(2-phenyl-2-oxoethyl)-3-(p-methoxyphcnyl sulfonyl hydrazinc carbonyl)<br>
pyridinium bromide and pharmaceulically acceptable salts thereof,<br>
(zf) 1-(2-phenyl-2-o.\oelhyl)-4-[2-(bcnzoyloxy) ethyl amino carbonyl] pyridinium<br>
bromide and pharmaceutically acceptable salts thereof, and<br>
(zg) 1-(2-elhoxy-2-oxocthyl)-4-(p-methancsulfonyl hydra/ine carbonyl) pyridinium<br>
bromide and pharmaceutically acceptable salts thereof.<br>
2. A process for the preparation of the compound as claimed in claim 1, which comprises :<br>
i) refluxing pyridinc derivative selected from :<br>
1. N,N" -bis(nicotinyl)hydrazinc<br>
2. 3-[(2-pyridyl)hydrazinocarbonyl]pyridine<br>
3. 3-|(2-methanesulfonyl)hydrazinocarbonyl]pyridine<br>
4. 3-[(2-benzoyloxy)cthylaminocarbonyl]pyridine<br>
5. 3-|(2-phyenylsuironyl)hydrazinocarbonyl]pyridine<br>
6. 3-|(2-acctoxy)ethyloxycarbonyl]pyridinc<br>
7. 3-|(2-ben/.oyloxy)ethyloxycarbonyl|pyridinc<br>
8. 3-[(2-methoxy)cthyloxycarbonyl]pyridine<br>
9. 3-[(2-phycnylaminocarbonyl)hydra/inocarbonyl|pyridinc<br>
10. 3-[(2-acetoxy)ethylaminocarbonyl]pyridine<br>
11. 3-((2-(4-methylphenyl sulfonyl)hydra/.inocarbonyl)]pyridine<br>
12. 3-[(2-benzoyl)- hydrazino carbonyl ]pyridinc<br>
13. 3-|(2-phenylmcthanc sulfonyl) hydrazino carbonyl ]pyridinc<br>
14. 3-[(2-(3- cyclohexylpropanoyl) hydrazino carbonyl]pyridine<br>
15. 3-[(2-methoxy)ethylaminocarbonyl ]pyridinc<br>
16. 3-| l-oxo-1-(2-methoxycarbonyl)pyridyl|hydrazino pyridinc<br>
with a quaternizing agent selected from the group comprising of :<br>
1. 2-bromoacetyl thiophene<br>
2. 2-chloroacetyl thiopene<br>
3. phenacylbromide<br>
4. phenacylchloride<br>
5. 2,4-dichlorophenacylbromide<br>
6. N- phenyl chloroacetamide<br>
7. N- cyclopropyl chloroacetamide<br>
8. cthylbromoacctatc<br>
9. bromo acetylfuran<br>
10. N- isopropylchloroacetamide<br>
11. N- chloroacetyl-2-pyrrolidinone<br>
12. chloroacetic acid<br>
in a solvent selected from the group comprising of methanol, ethanol, propanol, toluene or<br>
xylene under reflux for 6 to 48 hours.<br>
ii) isolating the compound from step (i)<br>
3. A pharmaceutical composition for treatment of diabetic complictions and aging related<br>
diseases which comprises a pharmaceutically effective amount of one or more compounds as<br>
claimed in claim 1 or pharmaceutically acceptable salt(s) thereof in admixture with a<br>
pharmaceutically acceptable carrier, diluent, solvent or excepient.<br>
4. The pharmaceutical composition as claimed in claim 3, in the form of an oral<br>
formulation.<br>
5. The pharmaceutical composition as claimed in claim 4, wherein said pharmaceutically<br>
acceptable carrier is selected from group consisting of starch, lactose, polyvinyl pyrolidone (K-<br>
30), talc and magnesium stearatc.<br>
6. The Pharmaceutical composition as claimed in claim 3 in the form of a parenteral<br>
formulation.<br>
7. A method for the preparation of a parenteral formulation as claimed in claim 6. which<br>
comprises dissolving one or more compounds as defined in claim 1, in polyethylene glycol 400<br>
and diluting the solution so obtained, with an isotonic solution or water to a desired<br>
concentration.<br>
8. Pharmaceutical composition as claimed in claim 5, in the form of a lotion, oral rinse and<br>
toothpaste.<br>
9. A process for preparation of pyridinium compounds substantially as herein described<br>
particularly with reference to the examples.<br>
10. A pharmaceutical composition substantially as herein described particularly with<br>
reference to examples.<br>
The invention discloses novel compounds of the pyridinium series useful for the<br>
management of diabetes and aging-related vascular complications, including kidney disease,<br>
nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth,<br>
by breaking performed AGE.<br>
The invention also discloses, method for preparation of the novel compounds of the series<br>
and pharmaceutical composition having one or more compounds as defined above as active<br>
ingredients.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LUNBTC0yMDAxLUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">604-CAL-2001-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LUNBTC0yMDAxLUZPUk0gMjcucGRm" target="_blank" style="word-wrap:break-word;">604-CAL-2001-FORM 27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LUNBTC0yMDAxLUZPUk0tMjcucGRm" target="_blank" style="word-wrap:break-word;">604-CAL-2001-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZm9ybSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtZ3BhLnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtbGV0dGVyIHBhdGVudC5wZGY=" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-letter patent.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjA0LWNhbC0yMDAxLWdyYW50ZWQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">604-cal-2001-granted-specification.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="214275-a-communication-and-a-power-control-method-with-transmit-diversity-in-a-mobile-communication-system-and-a-communication-and-receiving-device-therefor.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="214277-integral-multifunctional-system-for-motor-vehicle.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>214276</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>604/CAL/2001</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>06/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>08-Feb-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>07-Feb-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>19-Oct-2001</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>TORRENT PHARMACEUTICALS LTD,</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>CENTRAL PLAZA, 1ST FLOOR, ROOM #-106, 2/6, SARAT BOSE ROAD, CALCUTTA-700020, WEST BENGAL, INDIA.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SANKARANARAYANAN ALANGUDI</td>
											<td>B-7, SWASTIK PARK PREMCHANDNAGAR ROAD OPP. JUDGES&#x27;BUNGLOWS AHMEDABAD-380 015, INDIA.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K31/444,A61P9/10</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>09/939,702</td>
									<td>2001-08-28</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/214276-novel-compounds-for-the-management-of-aging-related-and-diabetic-vascular-complications-process-for-their-preparation-and-composition-comprising-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:56:34 GMT -->
</html>
